Serum osteoprotegerin levels in healthy controls and cancer patients

Allan Lipton, Suhail M. Ali, Kim Leitzel, Vernon Chinchilli, Lois Witters, Linda Engle, Donna Holloway, Pirow Bekker, Colin R. Dunstan

Research output: Contribution to journalArticle

114 Scopus citations

Abstract

Purpose: Osteoprotegerin (OPG) is a novel secreted member of the tumor necrosis factor receptor superfamily. In vitro, OPG blocks osteoclastogenesis in a dose-dependent manner. Serum OPG levels were assayed in cancer patients and healthy control subjects using an ELISA. Results: OPG levels in healthy controls were significantly higher in sera (0.17 ng/ml) than in plasma (0.14 ng/ml). OPG levels did not differ by age in either control group. Serum was available from patients with solid tumors (n = 145), hematological malignancies (n = 111), benign hematological disorders (n = 35), and rheumatologic diseases (n = 60). When adjusted for age and sex, there was no significant OPG elevation in the sera of patients with solid tumors compared with controls (0.2 versus 0.18 ng/ml). When analyzed by site of primary malignancy within the solid tumor patient group, serum OPG elevations were observed only in patients with colorectal cancer (0.29 ng/ml; P < 0.0001) and pancreatic cancer (0.35 ng/ml; P < 0.0001). When analyzed by site of metastasis within the solid tumor patient group, significant elevations in serum OPG were observed only in patients with liver metastases (0.29 ng/ml) and soft tissue metastases (0.21 ng/ml) but not in patients with bone or lung metastases. Within the hematological malignancy group, serum levels of OPG were significantly lower in patients with multiple myeloma (0.12 ng/ml) but were elevated in patients with Hodgkin's disease (0.29 ng/ ml) and Non-Hodgkin's Lymphoma (0.24 ng/ml; P = 0.048). Conclusions: Although some patients with malignancy have significant elevations of circulating OPG, these concentrations do not approach the level that would be expected to suppress osteoclast function.

Original languageEnglish (US)
Pages (from-to)2306-2310
Number of pages5
JournalClinical Cancer Research
Volume8
Issue number7
StatePublished - Jan 1 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Serum osteoprotegerin levels in healthy controls and cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Lipton, A., Ali, S. M., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., Holloway, D., Bekker, P., & Dunstan, C. R. (2002). Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research, 8(7), 2306-2310.